Anacor spots $7 million acne opportunity with Medicis
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals, the Palo Alto, California-based company that has had success with an ongoing deal with GlaxoSmithKline, has signed an R&D deal with Medicis Pharmaceutical for small-molecule, boron-based compounds for the potential treatment of acne.